Evolus Strategic Advantage and Growth slide image

Evolus Strategic Advantage and Growth

LOVVOLUS A COMPELLING INVESTMENT OPPORTUNITY UNDERPENETRATED AESTHETICS MARKET estimated to nearly double by 2028* VOLV W Total addressable market EXPANDS BY 78% with addition of HA filler portfolio* evolu Fully funded to PROFITABILITY BY 2025** Building a brand focused on the YOUNGER DEMOGRAPHIC GAINING MARKET SHARE IN THE U.S. while expanding internationally UNIQUE CASH-PAY BUSINESS MODEL powered by strong digital capabilities Source: Medical Insight, Inc. Cosmetic Neurotoxin Market Study, Jan. 2023, Medical Insights Dermal Filler Market Study, Mar. 2023 (www.miinews.com), BCG Aesthetic Research presented at IMCAS 2023 & company estimates. ** Within this presentation, "profitability" is defined as achieving positive non-GAAP operating income. De 5
View entire presentation